Predictors of Annual Pharmaceutical Costs in Australia for Community-Based Individuals with, or at Risk of, Cardiovascular Disease: Analysis of Australian Data from the REACH Registry

Author： Ademi Zanfina  

Publisher： Adis International

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.10, Iss.2, 2010-04, pp. : 85-94

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relationship Between Hematocrit Level and Cardiovascular Risk Factors in a Community‐Based Population

By  

Journal Of Clinical Laboratory Analysis (Electronic), Vol. 29, Iss. 4, 2015-07 ,pp. : 289-293

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cardiovascular risk screening program in Australian community pharmacies

By Peterson Gregory  

Pharmacy World and Science, Vol. 32, Iss. 3, 2010-06 ,pp. : 373-380

Springer Publishing Company

Access to resources Recommend Favorite

Pharmaceutical thrombosis prevention in cardiovascular disease

By Eriksson Mats   Christensen Kjeld   Lindahl Tomas L   Larsson Anders  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 4, 2002-04 ,pp. : 553-563

Informa Healthcare

Access to resources Recommend Favorite

Soaring costs of cardiovascular disease in the US

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 621, 2011-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Documentation of Chemotherapy Infusion Preparation Costs in Academic- and Community-Based Oncology Practices

By Brixner Diana I.   Oderda Gary M.   Nickman Nancy A.   Beveridge Roy   Jorgenson James A.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 3, 2006-03 ,pp. : 197-208

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite